Thank you for reaching out.
We’ll get back to you shortly.

Thank you for reaching out.
We’ll get back to you shortly.

Contact Us

Fragile X researcher takes on COVID-19

When SARS-CoV-2, the coronavirus responsible for the current pandemic, first emerged in the United States last year, Cara Westmark couldn’t sleep. Westmark studies fragile X syndrome, a genetic condition that often involves autism — and she couldn’t stop thinking about intriguing parallels she had noticed between fragile X and COVID-19, the disease SARS-CoV-2 causes.

Fragile X syndrome usually arises from mutations that silence the FMR1 gene, curbing production of a protein called FMRP and leading to runaway synthesis of other proteins. SARS-CoV-2, which contains a single long stretch of RNA, hijacks the same protein production machinery to crank out more virus, making people sick in the process. Could drugs designed to thwart protein synthesis help with both? “The idea kept me awake at night for a week,” says Westmark, assistant professor of neurology at the University of Wisconsin-Madison.

In August, Westmark outlined her idea in Frontiers in Cell and Developmental Biology, and she is about to begin testing a drug — developed with fragile X in mind — in mice exposed to SARS-CoV-2. Spectrum talked to Westmark about the painstaking work of collecting data during a pandemic and what her results might mean for people with fragile X syndrome.

Spectrum: What were you working on when the pandemic first hit?

Cara Westmark: When COVID hit, we were in the middle of a large study, and our campus sent all the students home because of the virus. At the time, I had two undergraduate students in the lab and the scientists who work with me. We work with a mouse model for fragile X syndrome. We study both pharmaceutical and dietary interventions to see if we can identify potential interventions.

We were able to get permission to stay open because we had had mice on special diets for several months and we were in the middle of testing, and it would have been a large loss. By the time we finished up [those tests], the campus was reopening in July, so we were fortunate that way.

S: How did you get the idea to repurpose fragile X drugs for COVID-19?

CW: The shutdown got me thinking about virus research. And I thought, “I wonder if there’s anything known about FMRP and viruses?” So I searched online, and there was one paper about FMRP and viruses. It showed that FMRP restricts the growth of Zika virus.

FMRP is a protein that’s not expressed in fragile X. This protein is a pivotal player in a lot of processes in the body. It binds to hundreds of different mRNAs in the brain, which affect numerous signaling pathways.

Being an RNA-binding protein and binding to a lot of RNAs, it would be expected that it would bind to viral RNA as well. [The work on Zika] virus got me thinking, “I wonder if FMRP would bind to SARS-CoV-2 RNA? And if it does, could we target the SARS-CoV-2 virus by using drugs that we’re already testing in the lab for fragile X?”

The drugs that we’re testing affect protein synthesis pathways. FMRP binds to numerous mRNAs to regulate their protein synthesis. When FMRP is bound, protein synthesis is inhibited. And when FMRP is released, protein synthesis proceeds. In the case of fragile X, when you don’t have any FMRP, you have this unregulated, excessive protein synthesis. A major focus of the fragile X field has been: What acts upstream of FMRP, and how can we target that to inhibit protein synthesis?

One candidate is metabotropic glutamate receptor 5 (mGluR5). There are numerous drugs out there that inhibit mGluR5, many of which have been tried in mice and in clinical trials to turn down protein synthesis and try to rescue phenotypes. My idea was: What if we could inhibit protein synthesis in the SARS-CoV-2 model with mGluR5 inhibitors?

S: How might mGluR5 inhibitors work in COVID-19?

CW: The virus is simple: It’s this shell with a single-stranded RNA molecule inside of it. It’s totally dependent on the host cell, on the human cell, to propagate. When it gets inside the cell, it starts recruiting host-cell proteins. And one of those could be FMRP, as well as other proteins — like ribosomes and other RNA-binding proteins — that are necessary for protein synthesis. If it can’t recruit those, and it can’t propagate itself, it can’t make viral proteins and replicate. If we could stall virus replication with mGluR5 inhibitors, that might slow the virus down until the body’s immune system can take over and start fighting it.

S: What was your first step after you had the idea to repurpose these drugs for COVID-19?

CW: I contacted everybody I could think of to get their help and opinion on how to move forward. It was a little slow going at first to get people on board. They thought it was a great idea but that we needed a lot more lab evidence to support it. So I contacted some folks on campus, including Yoshihiro Kawaoka. He has a lab here and a lab in Japan, and he was in Japan at the time. And he said, “Sure, we’ll test the drug.” He had a cell model that he could infect with the SARS-CoV-2 virus and then treat with a drug that we sent them and see if it would inhibit replication.

In April, we sent a lab-grade mGluR5 inhibitor called CTEP to Kawaoka’s lab in Japan, and he tested it. And the [results suggest the] drug did work. But it’s hard to know at this time if we could get the drug at high enough levels in vivo to inhibit the virus.

In the meantime, we did some computer and molecular modeling and found that SARS-CoV-2 RNA is filled with sites predicted to bind to FMRP. It could act as a sink if it’s binding a lot of FMRP. That could mean there’s not FMRP in the other parts of the cell to do its normal function.

There could be a misregulation in other proteins that cells need for normal function. For example, some people who are infected with the virus have what’s called a ‘cytokine storm’ of inflammatory proteins. People end up in the hospital needing treatment because of the inflammatory response. If FMRP has a normal function to inhibit the production of cytokines, and all of a sudden FMRP is all bound up to this virus, then you could make more cytokines or other proteins that are detrimental because you’ve lost your normal regulation of those proteins.

There’s some evidence in the literature for mGluR5 and FMRP being involved in some of these pathways. So that was a little more evidence that perhaps treating with an inhibitor of mGluR5 upstream and bypassing FMRP that way could be beneficial for treating SARS-CoV-2.

S: Where are you going with this next?

What we’re working on now is testing these drugs in an animal model. Mice are not infected by SARS-CoV-2, because they don’t have the receptor the virus uses to enter cells. But people have made transgenic animals that express this receptor. In the summer, we were able to acquire some of these mice, and I crossed them with our FMR1-knockout mice.

The first experiment will be to infect them with SARS-CoV-2, and we’ll see if the virus replicates more in the fragile X mice versus the wildtype mice. We would presume that in the mice missing FMRP, the infection would proceed much more rapidly and perhaps have more severe pathology. Maybe the mice will die more quickly than the other mice.

After we do that, the next step will be to pretreat with our mGluR5 inhibitor and see if we can slow down the virus and if we can rescue the animals that are infected.

S: How has your approach to the work changed as the pandemic has continued?

CW: At the beginning, I felt that sense of urgency when we knew so little about the virus. It was hard. I thought it was an exciting idea, but we needed so much data, and obviously the data takes a long time to collect. The vaccines and other drugs are out now, so it doesn’t feel as urgent right now as it did in, say, March through July and August.

But we’ve sent several grant applications out to continue the work. I hope something gets funded, because I’m hoping this will be more broadly applicable to multiple viruses. FMRP is such a strong RNA-binding protein. It’s already been shown to be involved with Zika virus, and if we show it’s involved with SARS-CoV-2, it’s likely that it binds to multiple viruses. Maybe this could be a general therapeutic strategy for — who knows? — the common cold or the next SARS virus or the next influenza virus. Maybe we can come up with a molecular mechanism to target that could be beneficial for multiple infections.

S: Are there any lessons that we can learn about fragile X or how to treat it from the work youre doing on SARS-CoV-2?

CW: One way it may help is if our fragile X mice are more susceptible to infection. Then the patients and family members may be more susceptible as well, and that would be good for them to know.

Also, maybe some of the drugs that are being tested for COVID-19 would be beneficial for fragile X. There’s a huge effort for repurposing for fragile X because it’s a rare disorder. The common antibiotic minocycline and the diabetes drug metformin are both used off-label in fragile X. If there are some drugs that are used to attenuate virus replication, maybe something like that could be repurposed for fragile X as well.

The post Fragile X researcher takes on COVID-19 appeared first on Spectrum | Autism Research News.

related articles

User Pic

Massive U.K. study finds racial and ethnic disparities in autism diagnoses

About 1.8 percent of schoolchildren in England are autistic, and the prevalence is high...

User Pic

Errors of omission: Why we are deeply concerned about research on autism therapies

Kristen Bottema-Beutel Associate professor, Boston University Shannon Crowley Gradua...

User Pic

Immune markers in newborns show complex relationship with autism odds

On defense: The way a baby’s immune system responds to changes in utero may influence h...

User Pic

Differing gene functions across species may pose problems for autism models

Misaligned gene expression maps suggest that some autism-linked genes play distinct rol...


google analytics policy

we may collect information about your computer, including your IP address, operating system and browser type, for system administration and in order to create reports. This is statistical data about our users' browsing actions and patters, and does not identify any individual.

The only cookies in use on our site are for Google Analytics. Google Analytis is aweb analytics tool that helps website owners understand how visitors engage with their website. GoogleAnalytics customers can view a variety of reports about how visitors interact with their website so that they can improve it.

Like many services, Google Analytics users first-party cookies to track visitor interactions as in our case, where they are used to collect information about how visitors use our site. We then use the information to compile reports and to help use improve our site.

Cookies contain information that is transferred to your computer's hard drive. These cookies are used to store information, such as the time that the current visit occured, whether the visitor has been to the site before and what site referred the visitor to the web page.

Google Analyticsw collets information anonymously. It reports website trends without identifying individual visitors. you can opt out of Google Analytics without affecting how your visit our site- for more information on opting our of being tracked by Google Analytics across all websites you use, visit this Google page


hipaa privacy

Compleat KiDZ


If you have any questions about this Notice of Privacy Practices, please contact our Privacy Officer, by telephone at (704) 824-7800 or in writing at 2675 Court Drive, Gastonia, NC 28054.
This Notice of Privacy Practices describes how we may use and disclose your protected health information to carry out treatment, payment or health care operations and for other purposes that are permitted or required by law. It also describes your rights to access and control your protected health information. Protected health information is information about you, including demographic information, that may identify you and that relates to your past, present or future physical or mental health or condition and related health care services.


We are required to abide by the terms of this Notice of Privacy Practices. We may change the terms of our Notice of Privacy Practices at any time. The new Notice of Privacy Practices will be effective for all protected health information that we maintain at that time. Upon your request, we will provide you with any revised Notice of Privacy Practices. You may request a revised version by calling or writing our Privacy Officer and requesting that a revised copy be sent to you in the mail or asking for one at the time of your next appointment.


Your protected health information may be used and disclosed by our office staff others outside of our office who are involved in your care and treatment for the purpose of providing health care services to you.
Your protected health information may also be used and disclosed to pay your health care bills and to support the operation of our practice.
Following are examples of the types of uses and disclosures of your protected health information that we are permitted to make. These examples are not meant to be exhaustive, but to describe the types of uses and disclosures that may be made by our office.

1. Treatment: We will use and disclose your protected health information to provide, coordinate, or manage your health care and any related services. This includes the coordination or management of your health care with another provider.
For example, we would disclose your protected health information, as necessary, to a home health agency that provides care to you. We will also disclose protected health information to other healthcare providers who may be treating you.
For example, your protected health information may be provided to a physician to whom you have been referred to ensure that the physician has the necessary information to diagnose or treat you. In addition, we may disclose your protected health information from time-to-time to other health care providers (e.g., a specialist or laboratory) who become involved in your care by providing assistance with your health care diagnosis or treatment to us.
2. Payment: We may use and disclose protected health information about you so that the treatment and services you receive at Compleat KiDZ may be billed to and payment may be collected from you, an insurance company, or a third party. This may include certain activities that your health insurance plan may undertake before it approves or pays for the health care services we recommend for you such as: making a determination of eligibility or coverage for insurance benefits, and reviewing services provided to you for medical necessity. For example, if you have a back injury, we may need to give your health plan information about your condition, supplies used, and services you received.
3. Healthcare Operations: We may use or disclose, as needed, your protected health information for healthcare operations. These uses and disclosures are necessary to run Compleat KiDZ and make sure that all of our patients receive quality care. For example, we ma)'use protected health information to review our treatment and services and to evaluate the performance of our staff in caring for you. We may also combine protected health information about many patients to decide what additional services Compleat KiDZ should offer, what services are not needed, and whether certain new treatments are effective. We may also disclose information to doctors, nurses, technicians, medical students, and other personnel for review and learning purposes, we may remove information that identifies you from this set of protected health information so others may use it to study health care and health care delivery without learning the identities of specific patients.
We may share your protected health information with third party "business associates" that perform various activities (for example, billing or transcription services) for our practice. Whenever an arrangement between our practice and a business associate involves the use or disclosure of your protected health information, we will have a written contract that contains terms that will protect the privacy of your protected health information.
We may use and / or disclose protected health information to contact you to, remind you about an appointment you have for treatment or medical care.
We may use or disclose your protected health information, as necessary, to provide you with information about treatment alternatives or other health--related benefits and services that may be of interest to you. You may contact our Privacy Officer to request that these materials not be sent to you.
4. Other Permitted and Required Uses and Disclosures That May Be Made Without Your Authorization or Opportunity to Agree and Object:
We may use or disclose your protected health information in the following situations without your authorization or providing you the opportunity to agree or object. These situations include:
(i) Required by Law: We may use or disclose your protected health information to the extent that the use or disclosure is required by law. The use or disclosure will be made in compliance with the law and will be limited d to the relevant requirements of the law. You will be notified, if required by law, of any such uses or disclosures.

(ii) Public Health: We may disclose your protected health information for public health activities and purposes to a public health authority that is permitted by law to collect or receive the information. For example, a disclosure may be made for the purpose of preventing or controlling disease, injury or disability.

(iii) Communicable Diseases: We may disclose your protected health information, if authorized by law, to a person who may have been exposed to a communicable disease or may otherwise be at risk of contracting or spreading the disease or condition.

(iv) Health Oversight: We may disclose protected health information to a health oversight agency for activities authorized by law, such as audits, investigations, and inspections. Oversight agencies seeking this information include government agencies t-rat oversee the health care system, government benefit programs, other government regulatory programs and civil rights laws.

(v) Abuse or Neglect: We may disclose your protected health information to a public health authority that is authorized by law to receive reports of child abuse or neglect. In addition, we may disclose your protected health information if we believe that you have been a victim of abuse, neglect or domestic violence to the governmental entity or agency authorized to receive such information. In this case, the disclosure will be made consistent with the requirements of applicable federal and state laws.

(vi) Legal Proceedings: We may disclose protected health information in the course of any judicial or administrative proceeding, in response to an order of a court or administrative tribunal (to the extent such disclosure is expressly authorized), or in certain conditions in response to a subpoena, discovery request or other lawful process.

(vii) Law Enforcement: We may also disclose protected health information, so long as applicable legal requirements are met, for law enforcement purposes, these law enforcement purposes include (1) legal processes and otherwise required by law, (2) limited information requests for identification and location purposes, (3) pertaining to victims of a crime, (4) suspicion that death has occurred as a result of criminal conduct, (5) in the event that a crime occurs on the premises of our practice, and (6) medical emergency (not on our premises) and it is likely that a crime has occurred.

(viii) Research: We may disclose your protected health information to researchers when their research has been approved by an institutional review board that has reviewed the research proposal and established protocols to ensure the privacy of your protected health information.

(ix) Criminal Activity: Consistent with applicable federal and state laws, we may disclose your protected health information, if we believe that the use or disclosure is necessary to prevent or lessen a serious and imminent threat to the health or safety of a person or the public. We may also disclose protected health information if it is necessary for law enforcement authorities to identify or apprehend an individual.

(x) Military Activity and National Security: When the appropriate conditions apply, we may use or disclose protected health information of individuals who are Armed Forces personnel (1) for activities deemed necessary by appropriate military command authorities; (2) for the purpose of a determination by the Department of Veterans Affairs of your eligibility for benefits, or (3) to foreign military authority if you are a member of that foreign military services. We may also disclose your protected health information to authorized federal officials for conducting national security and intelligence activities, including for the provision of protective services to the President or others legally authorized.

(xi) Workers' Compensation: We may disclose your protected health information as authorized to comply with workers' compensation laws and other similar legally established programs.
5. Other Permitted and Required Uses of Disclosures That Require Providing You the Opportunity to Agree or Object
We may use and disclose your protected health information in the following instances. You have the opportunity to agree or object to the use or disclosure of all or part of your protected health information. If you are not present or able to agree or object to the use or disclosure of the protected health information, then we may, using professional judgment, determine whether the disclosure is in your best interest.

Others Involved in Your Health Care or Payment for our Care:

Unless you object, we may disclose to a member of your family, a relative, a close friend or any other person you identify, your protected health information that directly relates to that person's involvement in your health care. If you are unable to agree or object to such a disclosure, we may disclose such information as necessary if we determine that it is in your best interest based on our professional judgment. We may use or disclose protected health information to notify or assist in notifying a family member, personal representative or any other person that is responsible for your care of your location, general condition or death. Finally, we may use or disclose your protected health information to an authorized public or private entity to assist in disaster relief efforts and to coordinate uses and disclosures to family or other individuals involved in your health care.
6. Uses and Disclosures of Protected Health Information Based upon Your Written Authorization Other uses and disclosures of your protected health information will be made only with your written authorization, unless otherwise permitted or required by law as described below. You may revoke this authorization in writing at any time. If you revoke your authorization, we will no longer use or disclose your protected health information for the reasons covered by your written authorization. Please understand that we are unable to take back any disclosures already made with your authorization.
Following is a statement of your rights with respect to your protected health information and a brief description of how you may exercise these rights
1. You have the right to inspect and copy your protected health information
This means you may inspect and obtain a copy of protected health information about you for so long as we maintain the protected health information. You may obtain your medical record that contains medical and billing records and any other records that we use for making decisions about you. As permitted by federal or state law, we may charge you a reasonable copy fee for a copy of your records.
2. You have the right to request a restriction of your protected health information
This means you may ask us not to use or disclose any part of your protected health information for the purposes of treatment, payment or health care operations. You may also request that any part of your protected health information not be disclosed to family members or friends who may be involved in your care or for notification purposes as described in this Notice of Privacy Practices. Your request must state the specific restriction requested and to whom you want the restriction to apply.

We are not required to agree to a restriction that you may request. If we agree to the requested restriction, we may not use or disclose your protected health information in violation of that restriction unless it is needed to provide emergency treatment. With this in mind, please discuss any restriction you wish to request with your health provider.

You may request a restriction by making your request in writing to our Privacy Officer. In your request, you must tell us (1) what information you want to limit; (2) whether you want to limit our use, disclosure, or both; and (3) to whom you want the limits to apply, for example, disclosures to your spouse.
3. You have the right to request to receive confidential communications from us by alternative means or at an alternative location
We will accommodate reasonable requests. We may also condition this accommodation by asking you for information as to how payment will be handled or specification of an alternative address or other method of contact. We will not request an explanation from you as to the basis for the request. Please make this request in writing to our Privacy Officer.
4. Your may have right to amend your protected health information
This means you may request an amendment of protected health information about you in a designated record set for so long as we maintain this information. In certain cases, we may deny your request for an amendment. If we deny your request for amendment, you have the right to file a statement of disagreement with us and we may prepare a rebuttal to your statement and will provide you with a copy of any such rebuttal. Please contact our Privacy Officer if you have questions about amending your medical record.
5. You have the right to receive an accounting of certain disclosures we have made, if any, of your protected health information This right applies to disclosures for purposes other than treatment, payment or health care operations as described in this Notice of Privacy Practices. It excludes disclosures we may have made to you if you authorized us to make the disclosure, to family members or friends involved in your care, or for notification purposes, for national security or intelligence, to law enforcement (as provided in the privacy rule) or correctional facilities, as part of a limited data set disclosure. The right to receive this information is subject to certain exceptions, restrictions and limitations.
6. You have the right to obtain a paper copy of this notice from us
upon request, even if you have agreed to accept this notice electronically.
You may complain to us or to the Secretary of Health and Human Services if you believe your privacy rights have been violated by us. You may file a complaint with us by notifying our Privacy Officer of your complaint. We will not retaliate against you for filing a complaint

You may contact our Privacy Officer at (704) 824-7800 for further information about the complaint process.

This notice was published and becomes effective on August l, 2011.